InBrain Pharma

About InBrain Pharma

InBrain Pharma is a biotech company specializing in brain infusion of drugs for the management of neurological disorders. Their unique approach focuses on treating advanced Parkinson's disease through continuous dopaminergic stimulation in the brain, using intracerebroventricular (i.c.v.) administration of dopamine. This method aims to offer personalized medicine for neurodegenerative disease management.

Products & Services

A-Dopamine:A Device Aided Therapy for Parkinson's disease, involving continuous administration of dopamine directly into the brain to manage advanced stage complications related to oral dopamine treatments (L-dopa). It aims to improve motor disability and quality of life without affecting walking, speech, or emotional disability.

Specialties

Brain infusion of drugs Neurological disorder management Pharmacological neuromodulation Parkinson's disease treatment Personalized medicine for neurodegenerative diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1900000 MR: - FA: €1.8 Million FAN: 1900000	D: 2025-05-12 FD: 2025-05-12	1 investors

Grant Latest

2025-05-12

$1.9M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Véronique Foutel

CEO

M

Matthieu Fisichella

CSO and Co-founder

D

David Devos

Preclinical and clinical scientific advisor, Co-founder

C

Caroline Moreau

Clinical Scientific Advisor

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

InBrain Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised